Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson's stock outlook is positively influenced by the company's robust performance, with total sales reaching $24.06 billion, surpassing both Stifel and Consensus projections, largely driven by growth in Innovative Medicine and MedTech segments. The anticipated separation of the Orthopaedic business is expected to enhance capital allocation, leading to increased investment in research and development and improved growth opportunities within MedTech, particularly in the cardiovascular and vision sectors. Furthermore, updated revenue estimates indicate a promising trajectory, with projections for 2026 now set at $100.42 billion, underscoring the company's strong operational growth dynamics and strategic adjustments to capitalize on high-potential therapies.

Bears say

Johnson & Johnson faces multiple fundamental challenges that contribute to a negative outlook on its stock, including the anticipated lower organic revenue growth due to decreased contributions from its pharmaceutical pipeline and the impending loss of exclusivity for key drugs. The company's MedTech division is projected to experience slower growth due to competitive pressures and the risks associated with product uptake, particularly in robotic-assisted surgery. Additionally, ongoing litigation and settlement costs, coupled with potential difficulties in integrating acquisitions, further complicate JNJ's financial stability and investor confidence.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.